PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.
TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) ( TSXV:PSYB ) (PsyBio), a biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders, announces the unaudited financial results of Leo Acquisition Corp. (now PsyBio Therapeutics Corp.) for the six month period ended December 31, 2020.
- TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) ( TSXV:PSYB ) (PsyBio), a biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders, announces the unaudited financial results of Leo Acquisition Corp. (now PsyBio Therapeutics Corp.) for the six month period ended December 31, 2020.
- PsyBio is a US-based biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders.
- Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements.
- Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date.